Cargando…

HER2 Amplification in p53-Mutated Endometrial Carcinomas

SIMPLE SUMMARY: Endometrial cancers with p53 mutations tend to recur and develop metastases more frequently. From this point of view, the detection of new potential therapeutic targets such as HER2 is particularly interesting. In this study, we demonstrated that overexpression of HER2 (++ or +++) wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balestra, Ambre, Larsimont, Denis, Noël, Jean-Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001224/ https://www.ncbi.nlm.nih.gov/pubmed/36900227 http://dx.doi.org/10.3390/cancers15051435

Ejemplares similares

P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma
por: Bouri, Sarah, et al.
Publicado: (2020)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma
por: Chang, Kuang-Leei, et al.
Publicado: (2016)

Performance of a HER2 testing algorithm specific for p53‐abnormal endometrial cancer
por: Vermij, Lisa, et al.
Publicado: (2021)

Correlation of HER2 With p53 and p63 in Urothelial Bladder Carcinoma
por: Ponnaboina, Divya Madhuri, et al.
Publicado: (2023)

PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium
por: Bienfait, Lucie, et al.
Publicado: (2018)

Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer
por: Ismail, Manal F., et al.
Publicado: (2009)

p53 Mutations and c‐erbB‐2 Amplification in Intraductal and Invasive Breast Carcinomas of High Histologic Grade
por: Tsuda, Hitoshi, et al.
Publicado: (1993)

KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
por: Bar, Julia K, et al.
Publicado: (2012)

Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility
por: Köbel, Martin, et al.
Publicado: (2019)

Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features
por: Kang, Eun Young, et al.
Publicado: (2021)

Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations
por: Yu, Qiong, et al.
Publicado: (2014)

P53 mutations in gastric carcinomas.
por: Seruca, R., et al.
Publicado: (1992)

p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans
por: Wild, Peter J, et al.
Publicado: (2012)

Effects of ectopic HER-2/neu gene expression on the COX-2/PGE(2)/P450arom signaling pathway in endometrial carcinoma cells: HER-2/neu gene expression in endometrial carcinoma cells
por: Li, Shu, et al.
Publicado: (2013)

Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients
por: Mirmalek, Seyed Abbas, et al.
Publicado: (2014)

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
por: Piha-Paul, Sarina A., et al.
Publicado: (2023)

Significance of TP53 Mutational Status-Associated Signature in the Progression and Prognosis of Endometrial Carcinoma
por: Chen, Ying, et al.
Publicado: (2022)

Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma.
por: Soong, R., et al.
Publicado: (1996)

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
por: Van Bockstal, Mieke R., et al.
Publicado: (2020)

Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma
por: Caria, Paola, et al.
Publicado: (2016)

Amplification and clinicopathological significance of HER-2 in Kazakh esophageal squamous cell carcinoma
por: Muhetaer, Aishanjiang, et al.
Publicado: (2020)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2(+) breast cancer
por: Janiszewska, Michalina, et al.
Publicado: (2015)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

Pleomorphic Invasive Lobular Carcinoma of the Breast With Extracellular Mucin and HER2 Amplification
por: Burky, Matthew J, et al.
Publicado: (2020)

Is HER2 amplification predictable by digital immunohistochemistry?
por: Micsik, Tamás, et al.
Publicado: (2013)

TP53 mutations among molecular subtypes of HER2-positive tumors
por: Helland, Å, et al.
Publicado: (2005)

HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder
por: Kim, Bohyun, et al.
Publicado: (2016)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
por: KATO, HIROAKI, et al.
Publicado: (2013)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas
por: NAKAYAMA, KENTARO, et al.
Publicado: (2015)

Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells
por: Melo dos Santos, Nataly, et al.
Publicado: (2019)

Abnormal accumulation of p53 predicts radioresistance leading to poor survival in patients with endometrial carcinoma
por: Akiyama, Azusa, et al.
Publicado: (2019)

Attenuation of p53 mutant as an approach for treatment Her2-positive cancer
por: Fedorova, Olga, et al.
Publicado: (2020)

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer
por: Konecny, G E, et al.
Publicado: (2009)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma.
por: Mineta, H., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_b4ih3ar1milcp4djsvk1rrfcpo